文献速递临床试验与 GCP基础与转化研究

抗阻运动训练通过脑血管机制治疗重性抑郁障碍的随机对照试验方案(RESIST试验)

Protocol for a randomized controlled trial of a resistance exercise training to treat major depression via cerebrovascular mechanisms (RESIST Trial).
PubMed 文献 · Trials · 2025-08-26

RESIST试验计划纳入200例DSM-5诊断且至少为轻度重性抑郁障碍的成人,随机接受16周每周两次抗阻运动训练,分为指南推荐的高剂量组(初始负荷为单次最大重复量的60%,n=100)与低剂量/假训练组(初始负荷为单次最大重复量的30%,n=100)。主要结局为临床医生评定的GRID-汉密尔顿抑郁评定量表和自评的抑郁症状快速量表所评估的抑郁症状严重程度;次要结局包括脑血流和一般自我效能感,并在第0、8、16、26、52周评估组间差异。

要点

  • 纳入200例DSM-5诊断且至少为轻度重性抑郁障碍的成人,随机分为高剂量抗阻运动训练组(n=100)与低剂量/假训练组(n=100)。
  • 干预为16周每周两次渐进性上下肢抗阻机器训练,高剂量组初始负荷为单次最大重复量的60%,低剂量/假训练组为30%。
  • 主要结局为抑郁症状严重程度(GRID-汉密尔顿抑郁评定量表和抑郁症状快速量表),次要结局为脑血流(脑血流速度和搏动性)及自我效能感。

核心结论

  • 该随机对照试验将严格检验抗阻运动训练治疗重性抑郁障碍的临床疗效,并探讨脑血管和心理机制;若疗效确认,抗阻运动训练可作为高度可转化、可及、低成本的替代治疗选择,届时仍需进一步开展实效性和实施性研究。

研究设计与样本

  • 随机对照试验,计划纳入200例DSM-5诊断且至少为轻度重性抑郁障碍的成人。
  • 参与者随机接受16周每周两次渐进性上下肢抗阻机器训练,高剂量组初始负荷为单次最大重复量的60%(n=100),低剂量/假训练组为30%(n=100)。
  • 评估访视安排在第0周(基线)、第8周、第16周(干预后)、第26周和第52周。

主要发现

  • 主要临床结局为抑郁症状严重程度,采用临床医生评定的GRID-汉密尔顿抑郁评定量表和自评的抑郁症状快速量表评估。
  • 次要结局包括脑血流(通过脑血流速度和搏动性评估)和自我效能感(通过新一般自我效能感量表和抗阻运动任务自我效能感评估),用于检验潜在中介因素。
  • 额外分析将探索治疗成功的预测因素以及参与者在主动干预结束后对抗阻运动训练的维持情况。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many adults with major depressive disorder (MDD) do not engage in treatment and may also not respond when current frontline treatments are completed. Resistance exercise training (RET) is an understudied behavioral treatment option, which may help with MDD management through improving cerebral blood flow that is commonly impaired in adults with MDD. The purpose of this study is to use gold-standard research methods to determine the validity (clinical efficacy) of RET for treating MDD and to determine potential cerebrovascular pathways through which RET might improve MDD symptoms. METHODS: This study will be a randomized controlled trial of 200 adults with DSM-5-diagnosed MDD of at least mild severity. Participants will be randomized to 16 weeks of twice-weekly RET at either guidelines-based high dose (60% one-repetition maximum initial load; n = 100) or a low-dose/SHAM (30% one-repetition maximum initial load; n = 100) progressive, upper- and lower-body program using resistance machines. The primary clinical outcomes of this trial are depressive symptom severity, assessed via clinician-rated GRID-Hamilton Depression Rating Scale and self-reported Quick Inventory of Depressive Symptomatology. Secondary outcomes that will examine potential mediators are cerebral blood flow (via cerebral blood velocity and pulsatility) and self-efficacy (via New General Self-Efficacy Scale and RET Task Self-Efficacy). Group differences will be evaluated during assessment visits at weeks 0 (Baseline), 8, 16 (Post-Intervention), 26, and 52. Additional analyses will explore predictors of treatment success and participants' maintenance of the RET past the active intervention. DISCUSSION: RET is an understudied behavioral treatment for MDD. This randomized controlled trial will critically build on previous studies by using a large sample size, rigorously examining potential (provocative, plausible) biological and psychological mechanisms of RET's hypothesized antidepressant effects, and determining potential persistent effects with short- and long-term follow-up assessments. If clinical efficacy is confirmed, RET would be added as a highly translatable, accessible, low-cost alternative treatment option for individuals with MDD. Further effectiveness and implementation research would be required if efficacy is confirmed in this trial. TRIAL REGISTRATION: This trial is registered on ClinicaTrials.gov (ID: NCT06110897; October 20th, 2023; https://clinicaltrials.gov/study/NCT06110897 ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Meyer JD, Smith SL, Gidley JM, et al. Protocol for a randomized controlled trial of a resistance exercise training to treat major depression via cerebrovascular mechanisms (RESIST Trial). Trials. 2025. PMID: 40859378. doi:10.1186/s13063-025-09025-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。